AI Medical Service is one of the world's first real-time endoscopic artificial intelligence (AI) developers that helps detect gastric cancer.
AI Medical Service's mission is to develop a system that supports endoscopist’s diagnosis for digestive tract including esophagus, stomach, and intestines.
AI Medical Service was founded in 2017 by Tomohiro Tada and is based in Toshima-ku, Tokyo, Japan.
AI Medical Service develops AI technology that brings together the wisdom of Japanese endoscopic specialists and supports endoscopic examinations of gastrointestinal organs, such as the esophagus, stomach, small intestine and large intestine.
AI Medical Service collaborates with approximately 80 medical institutions representing Japan in the field of gastrointestinal endoscopy to research and develop AI endoscopies.
The results have been widely accepted by experts all over the world, including the conference for Digestive Disease Week (DDW), the world's largest gastroenterology association, in which as many as 12 studies by AI Medical Service were selected for presentation including the one awarded as "Best of DDW."
AI Medical Service through its technology has potential for applications in other medical areas, they are dedicated to support endoscopists which has driven us to begin our research. The company is committed to create what is truly useful at clinical environment to save patients around the globe.
AI Medical Service is backed by Globis Capital Partners, World Innovation Lab (WiL) and Sony Innovation Fund by IGV (Innovation Growth Ventures). The company raised $42.9M from a "Series B" financing on Oct 4, 2019. The round brings AI Medical Service’s total funding so far to $57M.